3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
High Risk Myeloid Malignancies
1
Interventions
Specimen Handling
43
pembrolizumab
42
Biopsy
36
Magnetic Resonance Spectroscopy
34
Paclitaxel
21
Carboplatin
21
Gemcitabine
20
Nivolumab
19
Irinotecan
17
Radiosurgery
15
Cisplatin
13
Taxes
11
Pemetrexed
11
Ipilimumab
11
Fluorouracil
11
Cetuximab
11
trastuzumab deruxtecan
10
olaparib
10
Leucovorin
10
130-nm albumin-bound paclitaxel
10
abemaciclib
9
Oxaliplatin
9
Cyclophosphamide
9
Capecitabine
9
Bevacizumab
9
palbociclib
8
durvalumab
8
Fulvestrant
8
X-Rays
7
Trastuzumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Transplantation Conditioning
×
90 days
×
Clear all
NCT07627711
2026-06-04
DUAL-NK-PDAC
Beijing Biotech
Phase 1/2
Recruiting
42 enrolled
NCT07480928
2026-03-18
DUAL-NK-PDAC
Beijing Biotech
Phase 1/2
Recruiting
42 enrolled